Topical azithromycin or ofloxacin for endophthalmitis

Clinical Ophthalmology

Volumn 7, Issue 1, 2012, Pages 35-38

  Stewart, Michael W ^a   Stewart, Michael L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; OFLOXACIN;

COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG USE; ECONOMIC EVALUATION; ENDOPHTHALMITIS; HUMAN; INFECTION RATE; LETTER; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT INDICATION;

EID: 84872745320     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S39234     Document Type: Letter

References (5)

1. Romero-Aroca P, Sararols L, Arias L, Casaroli-Marano RP, Bassaganyas F. Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection. Clin Ophthalmol. 2012;6:1595-1599.
2. Regeneron. Bayer and Regeneron report positive top-line results of two Phase 3 studies with VEGF Trap-Eye in wet age-related macular degeneration. Available from: http://investor.regeneron.com/releasedetail.cfm?ReleaseID=552099. Accessed April 13, 2012.
3. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina. 2011;31(4):662-668.
4. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654-661.
5. Brechner FJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol. 2011;151(5):887-895.